Cover Image
市場調查報告書

人類結核菌感染疾病 - 開發中產品分析

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251603
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
人類結核菌感染疾病 - 開發中產品分析 Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014
出版日期: 2014年08月31日 內容資訊: 英文 76 Pages
簡介

人類結核菌感染疾病是由結核菌所引起的細菌性染疾病,會沿著淋巴結及血液擴大到各個器官。會藉由人與人之間的飛沫傳染,症狀有咳嗽,發熱,盜汗,胸部疼痛,疲勞感等。發病要素有藥物抗性菌的增加或HIV的感染等,可進行抗菌藥物的治療等。

本報告提供人類結核菌感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

人類結核菌感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/實驗室別

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • 鹽野義製藥
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Novartis AG
  • Oragenics, Inc.
  • Archivel Farma S.L.
  • NovoBiotic Pharmaceuticals, LLC
  • Spring Bank Pharmaceuticals, Inc.
  • Bioversys AG
  • Univalue Valorizacion, S.L.
  • GlobalAcorn

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • RUTI
  • ID-93
  • MU-1140
  • BV-6481
  • Small Molecule for Staphylococcus Aureus Infections and Mycobacterium Tuberculosis Infections
  • Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections
  • rAMtb-SIVgag Vaccine
  • NITD-349
  • Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections
  • Small Molecules for Bacterial and Viral Infections
  • SB-9922
  • Novo-23
  • Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis
  • Thuggacine
  • KKL-35
  • Small Molecule for Tuberculosis
  • Small Molecule 2 for Tuberculosis
  • Small Molecules to Inhibit CysK1 for Tuberculosis
  • GA-3MEP-TB
  • Small Molecules for Mycobacterium Tuberculosis Infections
  • Small Molecules for Mycobacterium Tuberculosis
  • Small Molecules for Infectious Disease
  • Small Molecules for Multiresistant Mycobacterium Tuberculosis Infections
  • Synthetic Peptide for Bacterial Infections

開發中產品的最新趨勢

暫停中的計劃

產品開發的里程碑

  • 熱門資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5369IDB

Summary

Global Markets Direct's, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014', provides an overview of the Mycobacterium Tuberculosis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mycobacterium Tuberculosis Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mycobacterium Tuberculosis Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mycobacterium Tuberculosis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mycobacterium Tuberculosis Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mycobacterium Tuberculosis Infections Overview
  • Therapeutics Development
    • Pipeline Products for Mycobacterium Tuberculosis Infections - Overview
    • Pipeline Products for Mycobacterium Tuberculosis Infections - Comparative Analysis
  • Mycobacterium Tuberculosis Infections - Therapeutics under Development by Companies
  • Mycobacterium Tuberculosis Infections - Therapeutics under Investigation by Universities/Institutes
  • Mycobacterium Tuberculosis Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Mycobacterium Tuberculosis Infections - Products under Development by Companies
  • Mycobacterium Tuberculosis Infections - Products under Investigation by Universities/Institutes
  • Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development
    • Shionogi & Co., Ltd.
    • AstraZeneca PLC
    • GlaxoSmithKline plc
    • Novartis AG
    • Oragenics, Inc.
    • Archivel Farma S.L.
    • NovoBiotic Pharmaceuticals, LLC
    • Spring Bank Pharmaceuticals, Inc.
    • Bioversys AG
    • Univalue Valorizacion, S.L.
    • GlobalAcorn
  • Mycobacterium Tuberculosis Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • RUTI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ID-93 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MU-1140 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BV-6481 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Staphylococcus Aureus Infections and Mycobacterium Tuberculosis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rAMtb-SIVgag Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NITD-349 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Bacterial and Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-9922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Novo-23 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Thuggacine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KKL-35 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CysK1 for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GA-3MEP-TB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Mycobacterium Tuberculosis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Mycobacterium Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multiresistant Mycobacterium Tuberculosis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mycobacterium Tuberculosis Infections - Recent Pipeline Updates
  • Mycobacterium Tuberculosis Infections - Dormant Projects
  • Mycobacterium Tuberculosis Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
      • Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin
      • Jun 17, 2013: Researchers Identify New Compound Effective Against Persistent And Drug-Resistant Tuberculosis
      • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2014
  • Number of Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Shionogi & Co., Ltd., H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by AstraZeneca PLC, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by GlaxoSmithKline plc, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Novartis AG, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Oragenics, Inc., H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Archivel Farma S.L., H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Bioversys AG, H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by Univalue Valorizacion, S.L., H2 2014
  • Mycobacterium Tuberculosis Infections - Pipeline by GlobalAcorn, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Mycobacterium Tuberculosis Infections Therapeutics - Recent Pipeline Updates, H2 2014
  • Mycobacterium Tuberculosis Infections - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2014
  • Number of Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top